Nanoviricides Inc. logo

Nanoviricides Inc. (NNVC)

Market Closed
12 Dec, 20:00
AMEX AMEX
$
1. 25
-0.05
-3.85%
$
22.51M Market Cap
- P/E Ratio
0% Div Yield
296,219 Volume
-0.73 Eps
$ 1.3
Previous Close
Day Range
1.25 1.3
Year Range
0.94 2.23
Want to track NNVC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 61 days
Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others SHELTON, CT / ACCESSWIRE / May 20, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the strong antiviral activity of NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV infection animal model. The animals in only the NV-387 treated group survived completely, as previously reported.

Accesswire | 1 year ago
NanoViricides reports strong antiviral activity of NV-387 against RSV

NanoViricides reports strong antiviral activity of NV-387 against RSV

NanoViricides (NYSE-A:NNVC) has reported that its antiviral drug candidate NV-387 demonstrated significant efficacy against respiratory syncytial virus (RSV) in a lethal lung infection animal model. The study showed that animals treated with NV-387 orally had normal lung histology and survived the infection, suggesting NV-387 could potentially cure RSV. In a comparative study, animals were administered NV-387 and ribavirin, another antiviral drug, for 11 days. The NV-387 treated group exhibited no lung damage and complete survival beyond the 21-day study period. Conversely, the ribavirin-treated group showed progressive lung pathology and did not survive past 14 days. "These results clearly demonstrate that NV-387 oral treatment would be of great clinical value for protecting infants and children from RSV," said Anil R. Diwan, the company's president and executive chairman. "We are very pleased with these results and plan on advancing NV-387 for the treatment of RSV infection into clinical trials as soon as possible." Currently, there is no approved treatment for RSV besides ribavirin, which is highly toxic. RSV causes morbidity and mortality among infants, children, and older adults, making the development of a safe and effective treatment an unmet medical need. Ben Broadbent, a member of the Bank of England's rate-setting committee, said the base rate could be cut at some point this summer. Deputy governor Broadbent, who steps down next month after 13 years on the Monetary Policy Committee (MPC), made the comment in a speech this morning. Following on from comments about the persistence of inflation, he said there is a "range of views" across the MPC on how persistent inflation could be. "In view of the rarity of events like this over the past, and the associated uncertainty about the future, that’s entirely understandable. "Whatever the priors of its individual members the MPC will continue to learn from the incoming data and, if things continue to evolve with its forecasts – forecasts that suggest policy will have to become less restrictive at some point – then it’s possible Bank Rate could be cut some time over the summer." His comments come ahead of the Office for National Statistics publishing the latest consumer price index on Wednesday, which is expected to show a sharp drop in the level of inflation, close to the MPC's 2% target. At the last policy meeting, two members of the committee voted for a cut, though the majority vote, including Broadbent, led to rates being kept at 5.25%. A month ago, the ONS data showed CPI inflation was 3.2% in March, with April forecast to see a big softening to 2.1% in the annual rate, as the month-on-month figure eases to 0.2% from 0.6%.

Proactiveinvestors | 1 year ago
NanoViricides is leveraging its unique nanoviricide platform technology to create first-in-class drugs against viruses

NanoViricides is leveraging its unique nanoviricide platform technology to create first-in-class drugs against viruses

Ben Broadbent, a member of the Bank of England's rate-setting committee, said the base rate could be cut at some point this summer. Deputy governor Broadbent, who steps down next month after 13 years on the Monetary Policy Committee (MPC), made the comment in a speech this morning. Following on from comments about the persistence of inflation, he said there is a "range of views" across the MPC on how persistent inflation could be. "In view of the rarity of events like this over the past, and the associated uncertainty about the future, that’s entirely understandable. "Whatever the priors of its individual members the MPC will continue to learn from the incoming data and, if things continue to evolve with its forecasts – forecasts that suggest policy will have to become less restrictive at some point – then it’s possible Bank Rate could be cut some time over the summer." His comments come ahead of the Office for National Statistics publishing the latest consumer price index on Wednesday, which is expected to show a sharp drop in the level of inflation, close to the MPC's 2% target. At the last policy meeting, two members of the committee voted for a cut, though the majority vote, including Broadbent, led to rates being kept at 5.25%. A month ago, the ONS data showed CPI inflation was 3.2% in March, with April forecast to see a big softening to 2.1% in the annual rate, as the month-on-month figure eases to 0.2% from 0.6%.

Proactiveinvestors | 1 year ago